newsfilter
← Latest News
PR Newswire·

Pulmatrix Issues Letter to Stockholders

LEXINGTON, Mass., Feb. 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technol